Blood conservation in orthopaedic surgery: The role of epoetin alfa

International Orthopaedics

Volumn 25, Issue 5, 2001, Pages 273-278

  Earnshaw, P ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ALLERGIC REACTION; BLOOD STORAGE; BLOOD TRANSFUSION; DISEASE TRANSMISSION; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

BLOOD TRANSFUSION, AUTOLOGOUS; EPOETIN ALFA; HUMANS; ORTHOPEDICS; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE PRESERVATION;

EID: 0034751264     PISSN: 03412695     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002640100261     Document Type: Review

References (42)

1. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study
2. An analysis of blood management in patients having a total hip or knee arthroplasty
3. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy
4. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement
5. Epoetin alfa facilitates presurgical autologous blood donation in non-anaemic patients scheduled for orthopaedic or cardiovascular surgery
6. Use of recombinant human erythropoietin outside the setting of uremia
7. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients
8. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery
9. Blood loss and transfusion management in spinal surgery
10. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
11. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation
12. Safety of the blood supply
13. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
14. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: Preoperative strategies for avoiding allogeneic blood exposure
15. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery
16. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy
17. Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy
18. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy
19. Transfusion medicine. First of two parts-blood transfusion
20. Erythropoietin therapy in the perioperative setting
21. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation
22. Preoperative autologous blood collection under erythropoietin stimulation. Preliminary results in patient selection, erythropoietin dosage and administration
23. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
24. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement
25. Blood management challenges in orthopedic oncology
26. Current options and approaches for blood management in orthopaedic surgery
27. Assessment of postoperative vigor in patients undergoing elective total joint arthroplasty: A concise patient- and caregiver-based instrument
28. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors
29. Allogeneic transfusion risks in the surgical patient
30. Transfusion safety: Avoiding unnecessary bloodshed
31. Developments in blood management: The potential therapeutic role for epoetin alfa in orthopedic trauma
32. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major Orthopedic surgery
33. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients
34. The risk of venous thromboembolism in the orthopedic patient: Epidemiological and physiological data
35. Recombinant human erythropoietin and blood management in pediatric spine surgery
36. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects
37. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
38. Blood management experience: Relationship between autologous blood donation and transfusion in orthopedic surgery
39. The international standard for recombinant DNA-derived erythropoietin: Collaborative study for four recombinant DNA-derived erythropoietins and two highly purified urinary erythropoietins
40. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty
41. Recombinant human erythropoietin for autologous blood donation: Effects on perioperative red blood cell and serum erythropoietin production
42. Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery